MISSISSAUGA, ON, Sept. 21, 2011 /CNW/ - MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser light therapy
and light imaging systems, announced today that MoleMate™, the unique
skin imaging system is FDA approved and now available for sale in the
US. MoleMate uses a hand-held device designed for office use that
utilizes light to view beneath suspicious moles in a pain free,
non-invasive manner, creating images for physicians to evaluate moles
and lesions often eliminating the need for skin biopsies resulting in
less pain, scarring, and expense. Physicians interested in learning
more should contact their local representative on the web at http://simsys-molemate.com.
"We are excited about launching MoleMate and the expanded features
version, SIMSYS™, and introducing US physicians to this amazing
technology, that had previously only been available outside the US, in
Australia and the United Kingdom. The US market alone is estimated to
be a $1 Billion dollar opportunity, and MoleMate and SIMSYS are the
only FDA approved and patent protected siascopy products in this
important health segment," stated Steve Guillen, President & CEO at
MedX Health Corp.
"I have used [MoleMate/SIMSYS] for six years and have found it an
invaluable tool. I chose this technology because it gives me extra
information about my patients' suspicious moles and lesions through the
additional views of the skin and helps me and the patients to come to a
more informed decision about removal." ― Dr. R.H. Falcon, Dermatologist, New York, NY
About MoleMate & SIMSYS
The FDA approved MoleMate and SIMSYS Skin Imaging Systems are a
significant advance in the early detection of potentially life
threatening moles and lesions. MoleMate and SIMSYS rapidly provide
accurate images of the pigment, blood, and collagen below the mole or
lesion. MoleMate and SIMSYS are both FDA approved and have a CE Mark
and are currently being sold in the European Community.
"Among the sophisticated equipment used by University of California
Irvine Melanoma Center physicians is a SIMSYS-MoleMate SIAscope, one of
the most advanced melanoma imaging systems in the world. For patients
with many moles, this computer imaging can make a big difference, it
decreases the number of biopsies needed, so they won't look like a
pincushion." - Dr. James G. Jakowatz, surgical oncologist and UC Irvine Melanoma
Center director - Dr. Janellen Smith, UC Irvine dermatologist and
co-director of the Pigmented Lesion Program, UC Irvine
MoleMate and the more robust system, SIMSYS, work with a hand-held
scanner, designed for office use, along with a specially designed
training CD. SIMSYS allows image capture and storage as well as
special features that can be used in visualizing and comparing moles.
SIMSYS will also support "mole mapping" early in 2012. Mole mapping is
a technique that physicians use on certain patients with 50-100 or more
moles where the entire surface of the patient's skin is photographed to
observe changes over time and then suspicious moles can be monitored
more closely or, if necessary, removed.
MoleMate is easy to incorporate into exams, and is easy for physicians
to learn how to use via the 60-90 minute training CD, as documented in
a study with general practitioners, who significantly improved their
ability to more accurately identify suspicious moles and lesion.
US Launch Underway
MedX Health has a direct sales team of 30 associates in addition to 4
regional specialty Distributors calling on dermatologists and primary
care physicians, representing a $1B market opportunity based on retail
prices between $5-$10K per system.
The website http://simsys-molemate.com contains additional information on MoleMate and SIMSYS, including
information on the technology behind these products, siascopy, as well
as product demos, and information on how other physicians have
integrated the skin cancer imaging system into their practice.
MoleMate and SIMSYS will also be presented at the American Academy of
Dermatology's 70th Annual Meeting, March 16-22, 2012, in San Diego, California, the
world's largest, most comprehensive dermatologic educational event.
Work with MoleMate and SIMSYS at booth #1361.
Sales in Europe and Australia
MoleMate and SIMSYS are currently being sold to physicians in Europe and
Australia, and now the US. Interested physicians and distributors
should contact MedX Health directly.
The Most Common Form of Cancer in the US
The Skin Cancer Foundation states that skin cancer is the most common
form of cancer in the US. Each year there are more new cases of skin
cancer than the combined incidence of cancers of the breast, prostrate,
lung and colon.
There are several types of skin cancers. Nearly 13 million people in
the US are living with a history of non-melanoma skin cancer, typically
diagnosed as basal cell carcinoma or squamous cell carcinoma. 800,000
people in the US are living with a history of melanoma. The survival
rate for patients whose melanoma is detected early, before the tumor
has penetrated the skin, is about 99 percent. The survival rate falls
to 15 percent for those with advanced disease.
Proctor & Gamble, LenioMed Ltd., and ScreenCancer, Inc., are research
and commercial partners that are funding the expansion of the
underlying technology, siascopy, into new consumer and wound care
About MedX Health Corp.
MedX is a twelve (12) year old Canadian company, headquartered in
Mississauga, Ontario (Toronto), and is a global leader in the design,
manufacturing and distribution of quality low level laser and light
therapy technologies for use in numerous medical settings, including
rehab/chiropractic, dental, wound care, and veterinary medicine,
providing patients with drug free and non-invasive treatment of tissue
damage and pain. MedX laser and light products are FDA approved, Health
Canada cleared, and CE Mark approved for use in North America as well
as the European Union. For a complete profile of MedX Health Corp. and
its products visit www.medxhealth.com.
This press release does not constitute an offer of any securities for
sale. This press release contains certain forward-looking statements
within the meaning of applicable Canadian securities legislation.
These forward-looking statements involve certain risks and
uncertainties that could cause actual results to differ, including,
without limitation, the company's limited operating history and history
of losses, the inability to successfully obtain further funding, the
inability to raise capital on terms acceptable to the company, the
inability to compete effectively in the marketplace, the inability to
complete the proposed acquisition and such other risks that could cause
the actual results to differ materially from those contained in the
company's projections or forward-looking statements. All
forward-looking statements in this press release are based on
information available to the company as of the date hereof, and the
company undertakes no obligation to update forward-looking statements
to reflect events or circumstances occurring after the date of this
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this press release.
SOURCE MedX Health Corp.
For further information:
President and Chief Executive Officer
MedX Health Corp. email@example.com
Phone: (905) 670-4428